Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218455

SCHEMBL23218455

SCHEMBL23218455

CCOC(=O)Cc1ccccc1OCc1c(C(=O)OCC)sc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFD P00746 13/20 0.51
▸ F11 P03951 6/20 0.50
▸ TPSB2 P20231 5/20 0.50
▸ PLAU P00749 2/20 0.50
▸ KLKB1 P03952 2/20 0.50
▸ PLG P00747 1/20 0.50
▸ F7 P08709 1/20 0.50
▸ MAPT P10636 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592714 0.90 CFD (0.42) CFDF11TPSB2PLAUKLKB1
SCHEMBL23219076 0.90 CFD (0.42) CFDF11TPSB2PLAUKLKB1
SCHEMBL29852478 0.86 MTNR1A (0.40) CFDF11TPSB2PLAUKLKB1
SCHEMBL23218804 0.86 MTNR1A (0.40) CFDF11TPSB2PLAUKLKB1
SCHEMBL23218062 0.83 CFD (0.56) CFDF11TPSB2PLAUKLKB1
SCHEMBL29853072 0.83 CFD (0.56) CFDF11TPSB2PLAUKLKB1
SCHEMBL23219045 0.83 CFD (0.66) CFDF11TPSB2PLAUKLKB1
SCHEMBL23218871 0.82 MAPT (0.42) CFDMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL23218709 0.82 CFD (0.59) CFDF11TPSB2PLAUKLKB1
SCHEMBL29853262 0.82 CFD (0.59) CFDF11TPSB2PLAUKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.